Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.42 |
| ▸ | LDHA | P00338 | 5/20 | 0.41 |
| ▸ | LDHB | P07195 | 4/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042851 | 0.83 | LDHA (0.38) | CSNK2A1LDHALDHBMAPK14 | |
| SCHEMBL1079473 | 0.82 | RAF1 (0.37) | MAPK14 | |
| SCHEMBL1078471 | 0.81 | BRAF (0.44) | MAPK14 | |
| SCHEMBL1148664 | 0.81 | LCK (0.53) | MAPK14 | |
| SCHEMBL1517029 | 0.76 | FGFR1 (0.43) | MAPK14 | |
| SCHEMBL1517063 | 0.75 | MAPK14 (0.42) | MAPK14 | |
| SCHEMBL1076599 | 0.75 | BRAF (0.44) | MAPK14 | |
| SCHEMBL1149165 | 0.71 | LCK (0.64) | MAPK14 | |
| SCHEMBL1517098 | 0.71 | FGFR1 (0.42) | CSNK2A1LDHALDHBCSNK2A2CSNK2B | |
| SCHEMBL1149056 | 0.69 | LCK (0.42) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269993-B1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269993-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | H1-2, H1-3, H1-0 | CSNK2A1 1205/4885LDHA 1678/4885LDHB 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.